{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:22:27Z","timestamp":1782894147806,"version":"3.54.5"},"reference-count":17,"publisher":"Editorial Committee of Annals of Thoracic and Cardiovascular Surgery","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ATCS","Ann Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2016]]},"DOI":"10.5761\/atcs.oa.16-00054","type":"journal-article","created":{"date-parts":[[2016,4,17]],"date-time":"2016-04-17T22:05:07Z","timestamp":1460930707000},"page":"161-167","source":"Crossref","is-referenced-by-count":11,"title":["Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study)"],"prefix":"10.5761","volume":"22","author":[{"given":"Akira","family":"Sezai","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Osaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yaoita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehito","family":"Arimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomi","family":"Shiono","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakuni","family":"Sakino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, Sekino Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3757","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Michael MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65: 809-48.","DOI":"10.1124\/pr.112.007278"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kurtz TW, Kajiya T. Differential pharmacology and benefit\/risk of azilsartan compared to other sartans. Vasc Health Risk Manag 2012; 8: 133-43.","DOI":"10.2147\/VHRM.S22595"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sezai A, Hata M, Niino T, et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 2010; 55: 1844-51.","DOI":"10.1016\/j.jacc.2009.11.085"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sezai A, Hata M, Niino T, et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study. J Am Coll Cardiol 2009; 54: 1058-64.","DOI":"10.1016\/j.jacc.2009.05.047"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sezai A, Nakata K, Iida M, et al. Early results of human atrial natriuretic peptide infusion in non-dialysis patients with chronic kidney disease undergoing isolated coronary artery bypass grafting: the NU-HIT trial for CKD-II. Ann Thorac Cardiovasc Surg 2014; 20: 217-22.","DOI":"10.5761\/atcs.oa.13.02252"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sezai A, Hata M, Yoshitake I, et al. Results of emergency coronary artery bypass grafting for acute myocardial infarction: importance of intraoperative and postoperative cardiac medical therapy. Ann Thorac Cardiovasc Surg 2012; 18: 338-46.","DOI":"10.5761\/atcs.oa.11.01821"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Sezai A, Soma M, Hata M, et al. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery\u2014investigation using a candesartan change-over study. Ann Thorac Cardiovasc Surg 2011; 17: 487-93.","DOI":"10.5761\/atcs.oa.11.01691"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Agata J, Ura N, Yoshida H, et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-74.","DOI":"10.1291\/hypres.29.865"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ohshima K, Mogi M, Nakaoka H, et al. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 2014; 63: e53-9.","DOI":"10.1161\/HYPERTENSIONAHA.113.02426"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tsutamoto T, Nishiyama K, Yamaji M, et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010; 33: 118-22.","DOI":"10.1038\/hr.2009.192"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28: 15-21.","DOI":"10.1093\/ajh\/hpu086"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tada Y, Yagi K, Uno M, et al. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan. J Stroke Cerebrovasc Dis 2015; 24: 1487-92.","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.03.015"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.","DOI":"10.1177\/147323000102900103"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-4.","DOI":"10.1093\/ajh\/7.12.1041"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13: 81-8.","DOI":"10.1111\/j.1751-7176.2010.00425.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Rakugi H, Enya K, Sugiura K, et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552-8.","DOI":"10.1038\/hr.2012.8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.","DOI":"10.1161\/HYPERTENSIONAHA.110.163402"}],"container-title":["Annals of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/22\/3\/22_oa.16-00054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:09:03Z","timestamp":1498302543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/22\/3\/22_oa.16-00054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5761\/atcs.oa.16-00054","relation":{},"ISSN":["1341-1098","2186-1005"],"issn-type":[{"value":"1341-1098","type":"print"},{"value":"2186-1005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}